Evolution of a Geriatric Syndrome: Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction

Journal of the American Geriatrics Society

Volumn 65, Issue 11, 2017, Pages 2431-2440

  Upadhya, Bharathi ^a   Pisani, Barbara ^a   Kitzman, Dalane W ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

aging; comorbidities; elderly; heart failure; preserved ejection fraction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; ANTIHYPERTENSIVE AGENT;

ADRENERGIC SYSTEM; AGING; ARTICLE; CALORIC RESTRICTION; CLINICAL FEATURE; COGNITIVE DEFECT; COMORBIDITY; DIETARY INTAKE; EXERCISE; FRAILTY; FUNCTIONAL STATUS; GERIATRIC DISORDER; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; LIFESTYLE MODIFICATION; MULTIPLE CHRONIC CONDITIONS; PATHOPHYSIOLOGY; PROPHYLAXIS; PROTEIN TARGETING; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; AGED; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE; KINESIOTHERAPY; MALE; PROCEDURES; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; EXERCISE THERAPY; FEMALE; HEART FAILURE; HEART VENTRICLES; HUMANS; MALE; PROGNOSIS; QUALITY OF LIFE; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 85034014970     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.15141     Document Type: Article

References (101)

1. Kitzman DW, Gardin JM, Gottdiener JS et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 2001;87:413–419.
2. Aurigemma GP, Gottdiener JS, Shemanski L et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol 2001;37:1042–1048.
3. Senni M, Tribouilloy CM, Rodeheffer RJ et al. Congestive heart failure in the community: A study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998;98:2282–2289.
4. Owan TE, Hodge DO, Herges RM et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251–259.
5. Dunlay SM, Redfield MM, Weston SA et al. Hospitalizations after heart failure diagnosis: A community perspective. J Am Coll Cardiol 2009;54:1695–1702.
6. Fonarow GC, Stough WG, Abraham WT et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007;50:768–777.
7. Gerber Y, Weston SA, Redfield MM et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 2015;175:996–1004.
8. Paulus W, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263–271.
9. Vaduganathan M, Patel RB, Michel A et al. Mode of death in heart failure with preserved ejection fraction. J Am Coll Cardiol 2017;69:556–569.
10. Pitt B, Pfeffer M, Assmann S et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–1392.
11. Klapholz M, Maurer M, Lowe AM et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: Results of the New York Heart Failure Registry. J Am Coll Cardiol 2004;43:1432–1438.
12. Yancy CW, Jessup M, Bozkurt B et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol 2017;70:776–803.
13. Kitzman DW, Little WC, Brubaker PH et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002;288:2144–2150.
14. Stavrakis S, Pakala A, Thomas J et al. Obesity, brain natriuretic peptide levels and mortality in patients hospitalized with heart failure and preserved left ventricular systolic function. Am J Med Sci 2013;345:211–217.
15. Kociol RD, McNulty SE, Hernandez AF et al. Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. Circ Heart Fail 2013;6:240–245.
16. Anand IS, Claggett B, Liu J et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: From the TOPCAT Trial. JACC Heart Fail 2017;5:241–252.
17. Sayama H, Nakamura Y, Saito N et al. Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Coron Artery Dis 1999;10:537–540.
18. Maisel AS, Clopton P, Krishnaswamy P et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: Results from the Breathing Not Properly (BNP) multinational study. Am Heart J 2004;147:1078–1084.
19. Luchi RJ, Snow E, Luche JM. Left ventricular function in hospitalized geriatric patients. J Am Geriatr Soc 1982;30:700–705.
20. Hunt SA, Abraham, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation 2005;112:e154–e235.
21. Redfield MM, Kitzman DW. Heart failure: A rose by another name? Congest Heart Fail 2006;12:166–168.
22. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004;350:1953–1959.
23. Kitzman DW, Upadhya B, Vasu S. What the dead can teach the living: The systemic nature of heart failure with preserved ejection fraction. Circulation 2015;131:522–524.
24. Mohammed SF, Hussain S, Mirzoyev SA et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015;131:550–559.
25. Borlaug BA. Exercise haemodynamics and outcome in patients with dyspnoea. Eur Heart J 2014;35:3085–3087.
26. Borlaug BA, Lam CSP, Roger VL et al. Contractility and ventricular systolic stiffening in hypertensive heart disease: Insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009;54:410–418.
27. Zile MR, Gottdiener JS, Hetzel SJ et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011;124:2491–2501.
28. Su MY, Lin LY, Tseng YH et al. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging 2014;7:991–997.
29. Kraigher-Krainer E, Shah AM, Gupta DK et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol 2014;63:446–456.
30. Borlaug BA, Kane GC, Melenovsky V et al. Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J 2016;37:3293–3302.
31. Brubaker PH, Joo KC, Stewart KP et al. Chronotropic incompetence and its contribution to exercise intolerance in older heart failure patients. J Cardiopulm Rehabil 2006;26:86–89.
32. Borlaug BA, Melenovsky V, Russell SD et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006;114:2138–2147.
33. Phan T, Shivu G, Weaver R et al. Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail 2010;3:29–34.
34. Redfield MM, Jacobsen SJ, Borlaug BA et al. Age- and gender-related ventricular-vascular stiffening: A community-based study. Circulation 2005;112:2254–2262.
35. Kitzman DW, Taffet G. Effects of aging on cardiovascular structure and function. In: Halter JB, Ouslander JG, Tinetti ME, Studenski SA, High KP, Asthana S, eds. Hazzard's Geriatric Medicine and Gerontology, 6th Ed. New York: McGraw Hill, 2009: pp. 883–895.
36. Freed BH, Daruwalla V, Cheng JY et al. Prognostic utility and clinical significance of cardiac mechanics in heart failure with preserved ejection fraction: Importance of left atrial strain. Circ Cardiovasc Imaging 2016;9:e003754.
37. Gottdiener JS, Kitzman DW, Aurigemma GP et al. Left atrial volume, geometry, and function in systolic and diastolic heart failure of persons >=65 years of age (The Cardiovascular Health Study). Am J Cardiol 2006;97:83–89.
38. Andersen MJ, Hwang SJ, Kane GC et al. Enhanced pulmonary vasodilator reserve and abnormal right ventricular: Pulmonary artery coupling in heart failure with preserved ejection fraction. Circ Heart Fail 2015;8:542–550.
39. Melenovsky V, Hwang S, Lin G et al. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 2014;35:3452–3462.
40. Mohammed SF, Hussain I, Abou Ezzeddine OF et al. Right ventricular function in heart failure with preserved ejection fraction: A community-based study. Circulation 2014;130:2310–2320.
41. Olson TP, Johnson BD, Borlaug BA. Impaired pulmonary diffusion in heart failure with preserved ejection fraction. JACC Heart Fail 2016;4:490–498.
42. Bhella PS, Prasad A, Heinicke K et al. Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur J Heart Fail 2011;13:1296–1304.
43. Haykowsky MJ, Brubaker PH, Morgan TM et al. Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: Role of lean body mass. J Gerontol A Biol Sci Med Sci 2013;68A:968–975.
44. Molina AJ, Bharadwaj MS, Van Horn C et al. Skeletal muscle mitochondrial content, oxidative capacity, and Mfn2 expression are reduced in older patients with heart failure and preserved ejection fraction and are related to exercise intolerance. JACC Heart Fail 2016;4:636–645.
45. Kitzman DW, Nicklas B, Kraus WE et al. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Physiol Heart Circ Physiol 2014;306:H1364–H1370.
46. Braunstein JB, Anderson GF, Gerstenblith G et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003;42:1226–1233.
47. Ather S, Chan W, Bozkurt B et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012;59:998–1005.
48. Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: Treat now by treating comorbidities. JAMA 2008;300:431–433.
49. Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol 2014;63:2817–2827.
50. Rusinaru D, Houpe D, Szymanski C et al. Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction. Eur J Heart Fail 2014;16:967–976.
51. Zakeri R, Borlaug BA, McNulty SE et al. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: A RELAX trial ancillary study. Circ Heart Fail 2014;7:123–130.
52. Lam CS, Rienstra M, Tay WT et al. Atrial fibrillation in heart failure with preserved ejection fraction: Association with exercise capacity, left ventricular filling pressures, natriuretic peptides, and left atrial volume. JACC Heart Fail 2017;5:92–98.
53. Cohen RA, Tong X. Vascular oxidative stress: The common link in hypertensive and diabetic vascular disease. J Cardiovasc Pharmacol 2010;55:308–316.
54. Boyer JK, Thanigaraj S, Schechtman KB et al. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004;93:870–875.
55. Ndumele CE, Coresh J, Lazo M et al. Obesity, subclinical myocardial injury, and incident heart failure. JACC Heart Fail 2014;2:600–607.
56. Obokata M, Reddy YN, Pislaru SV et al. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017;136:6–19.
57. Haykowsky MJ, Tomczak CR, Scott JM et al. Determinants of exercise intolerance in patients with heart failure and reduced or preserved ejection fraction. J Appl Physiol 2015;119:739–744.
58. Haykowsky M, Kouba EJ, Brubaker PH et al. Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Cardiol 2014;113:1211–1216.
59. Beavers K, Beavers D, Houston D et al. Associations between body composition and gait-speed decline: Results from the Health, Aging, and Body Composition study. Am J Clin Nutr 2013;97:552–560.
60. Normandin E, Houston DK, Nicklas BJ. Caloric restriction for treatment of geriatric obesity: Do the benefits outweigh the risks? Curr Opin Cardiol 2015;4:143–155.
61. Sharma K, Kass D. Heart Failure with preserved ejection fraction: Mechanisms, clinical features, and therapies. Circ Res 2014;115:79–96.
62. Hawkins NM, Petrie MC, Jhund PS et al. Heart failure and chronic obstructive pulmonary disease: Diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009;11:130–139.
63. Caruana L, Petrie MC, Davie AP et al. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from “diastolic heart failure” or from misdiagnosis? A prospective descriptive study. BMJ 2000;321:215–218.
64. Kitzman DW, Guazzi M. Impaired alveolar capillary membrane diffusion: A recently recognized contributor to exertional dyspnea in heart failure with preserved ejection fraction. JACC Heart Fail 2016;4:499–501.
65. Guazzi M, Borlaug B. Pulmonary hypertension due to left heart disease. Circulation 2012;126:975–990.
66. Bitter T, Faber L, Hering D et al. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail 2009;11:602–608.
67. Kasai T, Bradley TD. Obstructive sleep apnea and heart failure: Pathophysiologic and therapeutic implications. J Am Coll Cardiol 2011;57:119–127.
68. Dunlay SM, Weston SA, Redfield MM et al. Anemia and heart failure: A community study. Am J Med 2008;121:726–732.
69. Colombo P, Ganda A, Lin J et al. Inflammatory activation: Cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 2012;17:177–190.
70. Covinsky KE, Pierluissi E, Johnston CB. Hospitalization-associated disability: “She was probably able to ambulate, but I'm not sure”. JAMA 2011;306:1782–1793.
71. McNallan SM, Singh M, Chamberlain AM et al. Frailty and healthcare utilization among patients with heart failure in the community. JACC Heart Fail 2013;1:135–141.
72. Murad K, Goff DC Jr, Morgan TM et al. Burden of comorbidities and functional and cognitive impairments in elderly patients at the initial diagnosis of heart failure and their impact on total mortality: The Cardiovascular Health Study. JACC Heart Fail 2015;3:542–550.
73. Cogswell RJ, Norby FL, Gottesman RF et al. High prevalence of subclinical cerebral infarction in patients with heart failure with preserved ejection fraction. Eur J Heart Fail 2017 [Epub ahead of print].
74. Krumholz HM. Post-hospital syndrome: An acquired, transient condition of generalized risk. N Engl J Med 2013;368:100–102.
75. Franssen C, Chen S, Unger A et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail 2015;4:312–324.
76. Dhakal BP, Malhotra R, Murphy RM et al. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: The role of abnormal peripheral oxygen extraction. Circ Heart Fail 2015;8:286–294.
77. Kitzman D, Brubaker P, Morgan T et al. Exercise training in older patients with heart failure and preserved ejection fraction. Circ Heart Fail 2010;3:659–667.
78. Edelmann F, Gelbrich G, Dungen H et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: Results of the Ex-DHF (Exercise training in Diastolic Heart Failure) Pilot Study. J Am Coll Cardiol 2011;58:1780–1791.
79. Kitzman DW, Brubaker PH, Herrington DM et al. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: A randomized, controlled, single-blind trial. J Am Coll Cardiol 2013;62:584–592.
80. Angadi SS, Mookadam F, Lee CD et al. High-intensity interval training vs. moderate-intensity continuous exercise training in heart failure with preserved ejection fraction: A pilot study. J Appl Physiol 2014;95:15–27.
81. Pandey A, Parashar A, Kumbhani DJ et al. Exercise training in patients with heart failure and preserved ejection fraction: Meta-analysis of randomized control trials. Circ Heart Fail 2015;8:33–40.
82. Pandey A, Kitzman DW, Brubaker P et al. Response to endurance exercise training in older heart failure patients with preserved versus reduced ejection fraction. J Am Geriatr Soc 2017;65:1698–1704.
83. Haykowsky MJ, Brubaker PH, Stewart KP et al. Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction. J Am Coll Cardiol 2012;60:120–128.
84. Fujimoto N, Prasad A, Hastings JL et al. Cardiovascular effects of 1 year of progressive endurance exercise training in patients with heart failure with preserved ejection fraction. Am Heart J 2012;164:869–877.
85. Kitzman DW, Brubaker P, Morgan T et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: A randomised clinical trial. JAMA 2016;315:36–46.
86. Doukky R, Avery E, Mangla A et al. Impact of dietary sodium restriction on heart failure outcomes. JACC Heart Fail 2016;4:24–35.
87. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003;362:777–781.
88. Cleland JG, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338–2345.
89. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456–2467.
90. Edelmann F. Aldo-DHF investigators. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The ALDO-DHF randomized controlled trial. JAMA 2013;309:781–791.
91. Deswal A, Richardson P, Bozkurt B et al. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction Trial (RAAM-PEF). J Card Fail 2011;17:634–642.
92. Pfeffer MA, Claggett B, Assmann SF et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circulation 2015;131:34–42.
93. Abudiab MM, Redfield MM, Melenovsky V et al. Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction. Eur J Heart Fail 2013;15:776–785.
94. Redfield M, Chen H, Borlaug B et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. JAMA 2013;309:1268–1277.
95. Solomon S, Zile M, Pieske B et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387–1395.
96. Abraham WT, Adamson PB, Bourge RC et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. Lancet 2011;377:658–666.
97. Shah SJ, Kitzman DW, Borlaug BA et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: A multiorgan roadmap. Circulation 2016;134:73–90.
98. Wright JT Jr, Williamson JD, Whelton PK et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103–2116.
99. Williamson JD, Supiano MA, Applegate WB et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >/=75 years: A randomized clinical trial. JAMA 2016;315:2673–2682.
100. Machino-Ohtsuka T, Seo Y, Ishizu T et al. Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. J Am Coll Cardiol 2013;62:1857–1865.
101. Flacker JM. What is a geriatric syndrome anyway? J Am Geriatr Soc 2003;51:574–576.